• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Changing beta-blockers in heart failure: when is a class not a class?

作者信息

Aronson Jeffrey K

出版信息

Br J Gen Pract. 2008 Jun;58(551):387-9. doi: 10.3399/bjgp08X299317.

DOI:10.3399/bjgp08X299317
PMID:18505613
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2418988/
Abstract
摘要

相似文献

1
Changing beta-blockers in heart failure: when is a class not a class?心力衰竭中β受体阻滞剂的更换：何时一类药物不再属于同一类？
Br J Gen Pract. 2008 Jun;58(551):387-9. doi: 10.3399/bjgp08X299317.
2
Differences between bisoprolol and carvedilol in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized trial.比索洛尔和卡维地洛在慢性心力衰竭合并慢性阻塞性肺疾病患者中的差异：一项随机试验。
Respir Med. 2011 Oct;105 Suppl 1:S44-9. doi: 10.1016/S0954-6111(11)70010-5.
3
Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure.选择性和非选择性β受体阻滞剂对慢性心力衰竭患者体重、胰岛素抵抗及瘦素浓度的影响
Clin Res Cardiol. 2008 Jan;97(1):24-31. doi: 10.1007/s00392-007-0571-3. Epub 2007 Aug 17.
4
Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.β受体阻滞剂在慢性心力衰竭和慢性阻塞性肺疾病患者中的差异：一项随机交叉试验。
J Am Coll Cardiol. 2010 Apr 27;55(17):1780-7. doi: 10.1016/j.jacc.2010.01.024.
5
Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein.β-肾上腺素能受体拮抗剂作为药物转运体P-糖蛋白的底物和抑制剂的特性研究
Fundam Clin Pharmacol. 2006 Jun;20(3):273-82. doi: 10.1111/j.1472-8206.2006.00408.x.
6
Beta-blockers in congestive heart failure: the pharmacology of carvedilol, a vasodilating beta-blocker and antioxidant, and its therapeutic utility in congestive heart failure.β受体阻滞剂在充血性心力衰竭中的应用：卡维地洛的药理学，一种血管舒张性β受体阻滞剂和抗氧化剂，及其在充血性心力衰竭中的治疗作用。
Adv Pharmacol. 1998;42:611-5. doi: 10.1016/s1054-3589(08)60825-x.
7
Carvedilol for heart failure: renewed interest in beta blockers.用于治疗心力衰竭的卡维地洛：对β受体阻滞剂的新关注。
Cleve Clin J Med. 1997 Sep;64(8):415-22. doi: 10.3949/ccjm.64.8.415.
8
Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium.奈必洛尔、布新洛尔、美托洛尔和卡维地洛在人体心肌中无内在拟交感活性。
Br J Pharmacol. 2001 Aug;133(8):1330-8. doi: 10.1038/sj.bjp.0704188.
9
Comparative effects of carvedilol and metoprolol on regional vascular responses to adrenergic stimuli in normal subjects and patients with chronic heart failure.卡维地洛与美托洛尔对正常受试者及慢性心力衰竭患者局部血管对肾上腺素能刺激反应的比较效应。
Circulation. 2003 Aug 26;108(8):971-6. doi: 10.1161/01.CIR.0000085070.39873.B1. Epub 2003 Aug 11.
10
Serum carvedilol concentration and its relation to change in plasma brain natriuretic peptide level in the treatment of heart failure: a preliminary study.
Int J Clin Pharmacol Ther. 2003 Dec;41(12):578-86. doi: 10.5414/cpp41578.

引用本文的文献

1
Mass Spectrometry-Based Metabolomics Revealed Effects of Metronidazole on .基于质谱的代谢组学揭示了甲硝唑对……的影响。
Pharmaceuticals (Basel). 2023 Mar 7;16(3):408. doi: 10.3390/ph16030408.
2
Me-too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists.Me-too药物：历史、定义、实例及其与药品短缺和基本药物清单的相关性。
Br J Clin Pharmacol. 2020 Nov;86(11):2114-2122. doi: 10.1111/bcp.14327. Epub 2020 May 13.
3
Public understanding of drug therapy.公众对药物治疗的理解。
Br J Clin Pharmacol. 2012 Jun;73(6):943-7. doi: 10.1111/j.1365-2125.2012.04243.x.
4
Rational prescribing: the principles of drug selection.合理用药：药物选择的原则
Clin Med (Lond). 2009 Oct;9(5):481-5. doi: 10.7861/clinmedicine.9-5-481.
5
Trends and inequities in beta-blocker prescribing for heart failure.心力衰竭患者β受体阻滞剂处方的趋势与不平等现象。
Br J Gen Pract. 2008 Dec;58(557):862-9. doi: 10.3399/bjgp08X376195.

本文引用的文献

1
Identification and guided treatment of ventricular dysfunction in general practice using blood B-type natriuretic peptide.在全科医疗中使用血液B型利钠肽对心室功能障碍进行识别与指导治疗。
Br J Gen Pract. 2008 Jun;58(551):393-9. doi: 10.3399/bjgp08X299209.
2
The vasodilatory beta-blockers.血管舒张性β受体阻滞剂
Curr Hypertens Rep. 2007 Aug;9(4):269-77. doi: 10.1007/s11906-007-0050-2.
3
Vasodilatory mechanism of levobunolol on vascular smooth muscle cells.左布诺洛尔对血管平滑肌细胞的血管舒张机制。
Exp Eye Res. 2007 Jun;84(6):1039-46. doi: 10.1016/j.exer.2007.01.010. Epub 2007 Jan 27.
4
Nebivolol: new therapy update.奈必洛尔：新疗法进展
Cardiol Rev. 2006 Sep-Oct;14(5):259-64. doi: 10.1097/01.crd.0000223651.03023.8e.
5
Inhibition of endothelin-1 and KCL-induced increase of [CA2+]i by antiglaucoma drugs in cultured A7r5 vascular smooth-muscle cells.
J Ocul Pharmacol Ther. 2004 Jun;20(3):201-9. doi: 10.1089/1080768041223675.
6
Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter?β-肾上腺素能受体阻滞剂的心脏保护作用。亲脂性重要吗？
Basic Res Cardiol. 2000;95 Suppl 1:I41-5. doi: 10.1007/s003950070008.
7
Clinical relevance of pharmacokinetic differences between beta blockers.
Am J Cardiol. 1997 Nov 13;80(9B):15J-19J. doi: 10.1016/s0002-9149(97)00833-3.
8
The xamoterol experience in the treatment of heart failure.
Am J Cardiol. 1993 Mar 25;71(9):61C-64C. doi: 10.1016/0002-9149(93)90088-t.
9
An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists.α-和β-肾上腺素能受体联合拮抗剂的药效学特性及治疗潜力概述
Drugs. 1993 Apr;45(4):509-17. doi: 10.2165/00003495-199345040-00003.
10
Possible significance of the pharmacological differentiation of beta-blocking agents in hemodynamic effects in essential hypertension.β受体阻滞剂在原发性高血压血流动力学效应方面的药理差异的潜在意义。
Jpn Circ J. 1983 Mar;47(3):313-22. doi: 10.1253/jcj.47.313.